We co-founded DCx after having worked together for over a decade at Zymeworks where we held various executive and senior level responsibilities in the company.  Our direct experience in the research and development of Zanidatamab and its ADC version (Zani Zovodotin) gives us a competitive advantage and perspective in terms of the “do’s and don’ts” in biologics R&D.  That experience, coupled with our extensive network of thought-leaders and drug development experts enables us to set our sights on game-changing next generation drug conjugates to the maximum benefit of patients around the world.

​

More to come very soon.